Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib Consolidation Post-ASCT (NMSG 15/05)
NCT00417911Phase 3Completed
- Sponsor
- Nordic Myeloma Study Group
- Start
- Dec 2005
- Primary completion
- May 2009
- Modality
- Small Molecules, Modified Peptides
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of bortezomib in multiple myeloma (MM) (2 arms), sponsored by Nordic Myeloma Study Group. Primary endpoint: Event-Free Survival at 1 year. Started Dec 2005; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00417911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00417911.